Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled
To examine variation rate of Non-HDL with KI1106 comparison Atorvastatin monotherapy.
Randomly assigned to two groups (KI1106 or Atorvastatin monotherapy) after 4 weeks run-in
 period and prescribed KI1106 or Atorvastatin for 8 weeks.
Inclusion criteria:

 -  Screening Visit

 -  Age: 20-80

 -  High risk for cardiovascular disease according to NCEP APT III

 -  TG≥300mg/dL and 160mg/dL>LDL-C≥100mg/dL for subjects who were not taking statins
 for 4 weeks

 -  500mg/dL>TG≥200mg/dL and LDL-C<110mg/dL for subjects who were taking statins for
 4 weeks

 -  Baseline Visit

 -  500mg/dL>TG≥200mg/dL

 -  LDL-C<110mg/dL

 -  Reduction of LDL-C comparing screening visit

 Exclusion criteria:

 -  The patient has histories of acute artery disease within 3 months

 -  The patient has histories of operation revasculariation or aneurysm within 6 months

 -  The patient has histories of unexplained myalgia or diagnosed myalgia or
 rhabdomyolysis

 -  The patient has histories of effect able disease to the procedure and clinical trial
 result